Standard Biotools (LAB) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 17.54% |
| 10 | Standard Biotools | 258.10 Mn | -218.62 Mn | 10.54 Mn | -16.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.53% |
| Mar 31, 2026 | 118.37% |
| Dec 31, 2025 | -26.29% |
| Sep 30, 2025 | -5.64% |
| Jun 30, 2025 | 34.73% |
| Mar 31, 2025 | 67.32% |
| Sep 30, 2024 | 23.94% |
| Jun 30, 2024 | 10.88% |
| Mar 31, 2024 | -19.58% |
| Dec 31, 2023 | 40.65% |
| Sep 30, 2023 | -51.59% |
| Jun 30, 2023 | -9.40% |
| Mar 31, 2023 | -1.81% |
| Dec 31, 2022 | 141.45% |
| Sep 30, 2022 | -31.68% |
| Jun 30, 2022 | -66.56% |
| Mar 31, 2022 | -44.16% |
| Sep 30, 2021 | -50.10% |
| Jun 30, 2021 | -30.33% |
| Mar 31, 2021 | -12.41% |